Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

First Wave BioPharma, Inc. (FWBI)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.9400-0.0200 (-1.02%)
At close: 1:00PM EST
1.9200 -0.02 (-1.03%)
After hours: 04:43PM EST
Advertisement

First Wave BioPharma, Inc.

777 Yamato Road
Suite 502
Boca Raton, FL 33431
United States
561 589 7020
http://www.firstwavebio.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Mr. James R. Sapirstein M.B.A., R.Ph.Pres, CEO & Chairman622kN/A1961
Mr. Daniel H. SchneidermanChief Financial Officer356.03kN/A1978
Dr. James E. Pennington M.D.Chief Medical Officer324.8kN/A1943
Mr. Martin Krusin M.B.A.Sr. VP of Corp. Devel.N/AN/AN/A
Ms. Loreal McDonaldGen. CounselN/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, specializes in the development of targeted, non-systemic therapies for gastrointestinal diseases. The company is advancing a therapeutic development pipeline populated with various clinical stage programs built around its two proprietary technologies, known as niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. Its niclosamide portfolio is led by three clinical programs: FW-COV for COVID-19 gastrointestinal infections; FW-UP for ulcerative proctitis and ulcerative proctosigmoiditis; and FW-ICI-AC for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-associated colitis and diarrhea in advanced oncology patients. Two additional formulations of niclosamide, FW-UC (ulcerative colitis) and FW-CD (Crohn's disease) are focused to enter into pipeline development. The company is also advancing FW-EPI (adrulipase) for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

Corporate Governance

First Wave BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement